Cambridge drug developer Tiburio launches, targeting pituitary tumors with $31M
A Cambridge startup hoping to develop the first drug treatments to shrink dangerous tumors on the brain's pituitary gland launched Thursday with $31 million in funding.
Tiburio Therapeutics Inc. was spun out of Cambridge orphan disease accelerator Cydan this week with the Series A funding from New Enterprise Associates, Longitude Capital and Alexandria Real Estate Equities Inc.'s (NYSE: ARE) venture arm, Alexandria Venture Investments. Ibsen, which moved its U.S. headquarters to Massachusetts last…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Source Type: news
More News: Biotechnology | Brain | Brain Cancers | Funding | Health Management | Neurology | Pituitary Tumor